A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children

November 3, 2026 updated by: ModernaTX, Inc.

A Phase 1, Dose-escalation, Blinded Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children (9 to <18 Years of Age)

The purpose of this study is to evaluate safety, reactogenicity, and immunogenicity of mRNA-1010 in healthy children (9 to <18 years of age).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

96

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • California
      • Modesto, California, United States, 95355
        • Recruiting
        • Paradigm Clinical Research Centers, LLC
    • Colorado
      • Aurora, Colorado, United States, 80012
        • Recruiting
        • Paradigm Clinical Research Centers, LLC
    • Minnesota
      • Minneapolis, Minnesota, United States, 55402
        • Recruiting
        • Clinical Research Institute, Inc
    • Ohio
      • South Euclid, Ohio, United States, 44121
        • Recruiting
        • Senders Pediatrics
    • Texas
      • Houston, Texas, United States, 77055
        • Recruiting
        • West Houston Clinical Research Service
    • Virginia
      • Richmond, Virginia, United States, 23226
        • Recruiting
        • Clinical Research Partners, LLC.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

9 years to 17 years (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • 9 to <18 years of age inclusive, at the time of signing the informed consent/assent.
  • In the Investigator's opinion, the participants/participant's parent(s)/legally authorized representative (LAR(s)) demonstrate adequate understanding of the study requirements and are willing and physically able to comply with protocol mandated follow-up, including all procedures.
  • For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, and agreement to continue adequate contraception through 90 days following vaccine administration.

Exclusion Criteria:

  • History of anaphylaxis or severe hypersensitivity reaction requiring medical intervention after receipt of any mRNA vaccine or therapeutic or any components of an mRNA vaccine or therapeutic; influenza vaccine; or components of influenza vaccine, including egg protein.
  • Acutely ill or febrile (temperature ≥38.0 degrees Celsius (℃) [100.4 degrees Fahrenheit [°F]) within 72 hours prior to or at the Screening Visit or Day 1. Participants who are acutely ill or febrile may be scheduled for a separate dosing visit within the window specified for Screening.
  • History of a diagnosis or condition not specifically listed as exclusionary that, in the judgment of the Investigator, is clinically unstable, potentially affects participant safety, the assessment of study endpoints, the assessment of immune response, or adherence to study procedures.
  • Any prior systemic immunosuppressants, immunomodulators (for example, methotrexate, cyclosporine), or long-acting biological therapies that may affect immune responses (for example, dupilumab, omalizumab). Short courses (<7 days) of oral corticosteroids are allowed if completed at least 3 months prior to Day 1. Inhaled, nasal, topical steroids, and subcutaneous injected allergy immunotherapy (allergy shots) are allowed.
  • Received systemic immunoglobulins or blood products within 90 days prior to the Screening Visit or plans to receive them during the study.
  • Received any nonstudy vaccine authorized or approved by local health agency within 14 days (28 days for live vaccines and mRNA vaccines) prior to Day 1 (inclusive) or plans to receive any nonstudy vaccine within 28 days post study vaccine administration.
  • Donated ≥450 milliliters (mL) of blood products within 28 days prior to the Screening Visit or plans to donate blood products within 28 days post study vaccine administration.

Note: Other protocol-defined inclusion and exclusion criteria may apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Sequential Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: mRNA-1010 Low Dose

Participants will receive a single low dose of mRNA-1010 by intramuscular (IM) injection on Day 1.

Suspension for injection

Other Names:
  • Seasonal influenza vaccine
Experimental: mRNA-1010 Full Dose

Participants will receive a single full dose of mRNA-1010 by intramuscular (IM) injection on Day 1.

Suspension for injection

Other Names:
  • Seasonal influenza vaccine
Active Comparator: Fluarix Trivalent

Participants will receive a single dose of Fluarix Trivalent by IM injection on Day 1.

Suspension for injection

Other Names:
  • A standard dose licensed inactivated seasonal influenza trivalent flu vaccine

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibodies at Day 29, as Measured by Hemagglutination Inhibition (HAI) Assay
Time Frame: Day 29
Day 29
Percentage of Participants With HAI Titer ≥ 1:40 at Day 29
Time Frame: Day 29
Day 29
Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)
Time Frame: Up to Day 7 (7 days after vaccination)
Up to Day 7 (7 days after vaccination)
Number of Participants with Unsolicited Adverse Events (AEs)
Time Frame: Up to Day 28 (28 days after vaccination)
Up to Day 28 (28 days after vaccination)
Number of Participants with AEs Leading to Discontinuation, Serious Adverse Events (SAEs), or Adverse Events of Special Interest (AESI)
Time Frame: Day 1 through Day 365
Day 1 through Day 365
Number of Participants with Medically Attended AEs (MAAEs)
Time Frame: Day 1 through Day 181
Day 1 through Day 181
Percentage of Participants Reaching Seroconversion, as Measured by HAI Assay
Time Frame: Day 29

Seroconversion is defined as either a pre-vaccination HAI titer <1:10 and a post-vaccination titer ≥1:40 or a pre-vaccination HAI titer ≥1:10 and a minimum 4-fold rise in post-vaccination HAI antibody titer.

Day 29
Geometric Mean Fold Rise (GMFR) of Anti-HA antibodies, as Measured by HAI Assays
Time Frame: Day 29
Day 29

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 7, 2026

Primary Completion (Estimated)

December 7, 2027

Study Completion (Estimated)

December 7, 2027

Study Registration Dates

First Submitted

October 6, 2026

First Submitted That Met QC Criteria

October 6, 2026

First Posted (Actual)

October 13, 2026

Study Record Updates

Last Update Posted (Actual)

November 5, 2026

Last Update Submitted That Met QC Criteria

November 3, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • mRNA-1010-P102

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.